Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin Berry

Showing results (541-550 of 698) with videos related to

Pageof 70
Sort By:
The New England Journal of Medicine|August 28, 2018
Coronary CT Angiography and 5-Year Risk of Myocardial Infarction, David E Newby, Philip D Adamson, et al.
Heart (British Cardiac Society)|December 16, 2023
Very early invasive strategy in higher risk non-ST-elevation acute coronary syndrome: the RAPID NSTEMI trialThomas A Kite, Andrew Ladwiniec, John P Greenwood, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|May 4, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 19, 2023
Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trialAmerjeet S Banning, Manel Sabaté, Martin Orban, et al.
Journal of Clinical Pharmacology|July 6, 2025
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse EffectsJessica Chadwick, Colin Berry, Meredith A Carpenter, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|May 4, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Environmental Toxicology and Pharmacology|May 12, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Journal of Toxicology and Environmental Health. Part A|June 20, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Archives of Toxicology|June 10, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
American Heart Journal|March 11, 2025
Rationale and design of the ILIAS ANOCA clinical trial: A blinded-arm controlled trial for routine ad-hoc coronary function testingCoen K M Boerhout, Hanae F Namba, Tommy Liu, et al.
Pageof 70

Showing results (541-550 of 698) with videos related to

Sort By:
Pageof 70
The New England Journal of Medicine|August 28, 2018
Coronary CT Angiography and 5-Year Risk of Myocardial Infarction, David E Newby, Philip D Adamson, et al.
Heart (British Cardiac Society)|December 16, 2023
Very early invasive strategy in higher risk non-ST-elevation acute coronary syndrome: the RAPID NSTEMI trialThomas A Kite, Andrew Ladwiniec, John P Greenwood, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|May 4, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 19, 2023
Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trialAmerjeet S Banning, Manel Sabaté, Martin Orban, et al.
Journal of Clinical Pharmacology|July 6, 2025
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse EffectsJessica Chadwick, Colin Berry, Meredith A Carpenter, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|May 4, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Environmental Toxicology and Pharmacology|May 12, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Journal of Toxicology and Environmental Health. Part A|June 20, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Archives of Toxicology|June 10, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
American Heart Journal|March 11, 2025
Rationale and design of the ILIAS ANOCA clinical trial: A blinded-arm controlled trial for routine ad-hoc coronary function testingCoen K M Boerhout, Hanae F Namba, Tommy Liu, et al.
Pageof 70